Jordi Codony‐Servat

Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells.

Jordi Codony‐Servat, Joan Albanell, Federico Rojo et al. · PubMed · 2001 · 775 citations

Her2 Ectodomain Cleavage, Breast Oncology, Biochemistry +15

Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments.

Joan Albanell, Jordi Codony‐Servat, Federico Rojo et al. · PubMed · 2001 · 275 citations

Epidermal Growth Factor, Extracellular Signal-regulated Kinases, Pathology +19

Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells.

Jordi Codony‐Servat, Joan Albanell, Juan Carlos López-Talavera et al. · PubMed · 1999 · 238 citations

Breast Oncology, Molecular Biology, Cancer Biology +18

Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer

Kirstine Jacobsen, Jordi Bertrán-Alamillo, Miguel Ángel Molina‐Vila et al. · Nature Communications · 2017 · 181 citations · Full text

Interleukin 6, a Nuclear Factor-κB Target, Predicts Resistance to Docetaxel in Hormone-Independent Prostate Cancer and Nuclear Factor-κB Inhibition by PS-1145 Enhances Docetaxel Antitumor Activity

Josep Domingo‐Domenech, Cristina Oliva, Ana Rovira et al. · Clinical Cancer Research · 2006 · 169 citations